Right Where Care Begins
PolyPid is an innovative biopharmaceutical company dedicated to improving patient outcomes by developing long-acting, controlled-release medicines that deliver therapy precisely at the site of care, improving outcomes across surgical care, metabolic diseases, and beyond.
About UsRight Where Care Begins
PolyPid has entered an exclusive commercialization partnership with Azurity Pharmaceuticals for D-PLEX₁₀₀ in the U.S. and Canada valued at over $320 million
Read the announcement
X
Redefining the Surgical Standard
Our lead product, D-PLEX100, incorporates the proprietary Kynatrix™ technology and represents a first-in-class incisional prophylactic therapy for the prevention of surgical site infections (SSIs). It introduces long-awaited advancement in SSI prevention by enabling localized, prolonged antibiotic exposure directly at the surgical incision.
By delivering concentrated, broad-spectrum antibiotics at the incision site for 30 days, the most critical postoperative risk period. D-PLEX100 has demonstrated a clinically meaningful 60% reduction in surgical site infections compared with standard of care.
Constant and Consistent Drug Release
The Kynatrix™ technology enables customizable, localized, extended drug delivery over periods ranging from days to weeks, without burst effects, ensuring linear, high-concentration exposure across a broad range of therapeutic agents.
Our technology
Novel, Proprietary Technology
Validated, Clinically Proven
Unmatched Application Versatility
Robust Innovative Pipeline
Contact Us
